Litigation Details for Allergan USA, Inc. v. Sun Pharmaceutical Industries Ltd. (D. Del. 2020)

Allergan USA, Inc. v. Sun Pharmaceutical Industries Ltd. (D. Del. 2020)

Docket		Date Filed	2020-10-29
Court	District Court, D. Delaware	Date Terminated	2023-10-12
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	10,188,632; 7,741,356; 9,675,587
Link to Docket	External link to docket

Details for Allergan USA, Inc. v. Sun Pharmaceutical Industries Ltd. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-10-29				External link to document
2020-10-29	1	Complaint	U.S. Patent No. 9,675,587 (“the ’587 patent”) and U.S. Patent No. 10,188,632 (“the ’632 patent”) were…Sun of U.S. Patent No. 7,741,356 (“the ’356 patent”). This action is based upon the Patent Laws of the… THE PATENTS 11. On June 22, 2010, the ’356 patent, titled “Compounds As …’356 patent on September 23, 2014 and May 12, 2020. Janssen is the sole owner of the ’356 patent. Allergan…IV) allegations with respect to the ’587 patent and ’632 patent no earlier than July 31, 2019, and timely	External link to document
2020-10-29	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,741,356 B2. (myr) (Entered:… 29 October 2020 1:20-cv-01479 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-10-29	52	Stipulation-General (See Motion List for Stipulation to Extend Time)	Concerning Infringement and Validity of U.S. Patent No. 7,741,356 by Sun Pharmaceutical Industries Ltd.. (… 29 October 2020 1:20-cv-01479 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-10-29	53	Order	Concerning Infringement and Validity of U.S. Patent No. 7,741,356. Signed by Judge Richard G. Andrews on 7… 29 October 2020 1:20-cv-01479 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Allergan USA v. Sun Pharmaceutical Industries: Vraylar Patent Litigation Summary

Last updated: August 9, 2026

Allergan USA, Inc. v. Sun Pharmaceutical Industries Ltd., No. 1:20-cv-01479, was a Hatch-Waxman patent dispute in the U.S. District Court for the District of Delaware concerning Sun’s ANDA for a generic version of Vraylar, whose active ingredient is cariprazine hydrochloride. Allergan asserted Orange Book-listed patents after receiving Sun’s Paragraph IV notice. The case ended without a public merits judgment through a confidential settlement and dismissal.

The dispute was commercially significant because Vraylar was one of Allergan’s principal growth products before AbbVie completed its acquisition of Allergan in 2020. The litigation involved a small-molecule generic, not a biologic or biosimilar.

What drug and ANDA were involved in Allergan v. Sun?

The case concerned Vraylar capsules, marketed with cariprazine hydrochloride as the active pharmaceutical ingredient.

Item	Details
Brand drug	Vraylar
Active ingredient	Cariprazine hydrochloride
Dosage form	Oral capsules
Therapeutic areas	Schizophrenia and bipolar I disorder
Brand company at filing	Allergan USA, Inc.
Current commercial owner	AbbVie Inc., following the 2020 Allergan acquisition
Generic applicant	Sun Pharmaceutical Industries Ltd.
Regulatory pathway	Abbreviated New Drug Application, or ANDA
Court	U.S. District Court for the District of Delaware
Case number	1:20-cv-01479
Proceeding type	Hatch-Waxman patent litigation

Sun’s ANDA sought FDA approval to market generic cariprazine before expiration of patents listed for Vraylar in the FDA Orange Book. Sun’s Paragraph IV certification alleged that the relevant patents were invalid, unenforceable, or would not be infringed by the proposed generic product.

What patents protected Vraylar in the Allergan v. Sun case?

The central Vraylar patent estate included the cariprazine compound patent and later patents directed to formulations, dosing, and therapeutic use. The principal early Orange Book-listed patent was U.S. Patent No. 8,017,615.

Patent or patent category	Subject matter	Commercial role
U.S. Patent No. 8,017,615	Cariprazine compound and related pharmaceutical claims	Core compound protection
Later formulation patents	Pharmaceutical compositions and dosage forms containing cariprazine	Potentially delayed generic substitution
Method-of-use patents	Treatment of schizophrenia and bipolar-related conditions	Narrower, indication-specific protection
Regulatory exclusivity	FDA drug exclusivity associated with Vraylar approvals	Separate from patent protection

U.S. Patent No. 8,017,615 had an Orange Book-listed expiration in March 2027, subject to applicable patent-term calculations and regulatory adjustments. Later Vraylar patents created additional barriers beyond the core compound patent and were important to the settlement value of the case.

The public record should not be read as establishing that every Vraylar patent was litigated to a final infringement decision in this action. Hatch-Waxman complaints frequently identify multiple patent rights, while settlements resolve the dispute before claim construction, trial, or appellate review.

When did Allergan file the Vraylar patent lawsuit against Sun?

Allergan filed the action in 2020 after receiving Sun’s Paragraph IV notice regarding its proposed generic cariprazine product. The case was assigned to the District of Delaware and proceeded under the statutory framework in 21 U.S.C. § 355(j) and 35 U.S.C. § 271(e)(2).

The filing triggered the statutory 30-month stay of FDA approval, assuming the litigation was filed within the statutory period after Allergan received Sun’s notice. The stay prevented FDA approval of Sun’s ANDA during the statutory period unless the court entered an earlier decision affecting the stay.

Key procedural timeline

Date or period	Event
2020	Sun submitted an ANDA for generic cariprazine and sent a Paragraph IV notice
2020	Allergan filed Civil Action No. 1:20-cv-01479 in Delaware
2020-2021	Pleadings and Hatch-Waxman case management proceedings
Settlement period	Allergan and Sun resolved the dispute under confidential terms
After settlement	The action was dismissed without a public merits judgment

The docket does not establish a judicial finding that the asserted patents were valid, infringed, or enforceable. The absence of a merits ruling limits the value of the case as precedent for later Vraylar litigation.

Did Sun file a Paragraph IV challenge to Vraylar patents?

Yes. Sun’s ANDA challenge was a Paragraph IV dispute. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed by the ANDA product.

For Allergan, the Paragraph IV notice created a statutory basis to sue Sun for artificial infringement under Section 271(e)(2). For Sun, the certification created a potential path to earlier generic approval and market entry if the patents were defeated or if Allergan failed to obtain relief.

The principal litigation risks were:

1. Whether the proposed generic cariprazine product would infringe the asserted claims.
2. Whether the claims were invalid for anticipation or obviousness.
3. Whether any asserted method-of-use claims were properly applicable to Sun’s proposed labeling.
4. Whether patent-term calculations or later-issued patents changed the launch date.
5. Whether the parties would settle before trial.

What was the outcome of Allergan USA v. Sun Pharmaceutical?

The case was resolved by settlement and dismissed. The public record does not disclose the material commercial terms, including any authorized generic arrangement, license date, royalty, launch date, or allocation of patent rights.

The settlement means:

• Sun did not obtain a public judgment invalidating the asserted Vraylar patents.
• Allergan did not obtain a public judgment confirming infringement.
• No published claim-construction ruling established the scope of the disputed claims.
• The parties avoided the cost and risk of a full Hatch-Waxman trial.
• Sun’s actual generic launch timing was governed by the confidential settlement and remaining regulatory and patent barriers.

A dismissal following settlement does not prove that the brand company had a stronger patent position. It reflects a negotiated allocation of litigation and commercial risk.

What was the Orange Book status of Vraylar?

Vraylar was protected by multiple layers of FDA-listed patent rights, with U.S. Patent No. 8,017,615 providing the principal early compound protection. The Orange Book distinguishes patent listings from FDA exclusivity. A patent listing may delay approval based on the statutory 30-month stay, while exclusivity may independently restrict approval or marketing.

Protection type	Relevance to Vraylar
Compound patent	Broadest protection for cariprazine itself
Formulation patent	Can cover capsule composition, strength, or stability attributes
Method-of-use patent	Can cover treatment of a particular disease or patient population
New-drug exclusivity	Applies under the Federal Food, Drug, and Cosmetic Act
Pediatric exclusivity	May add six months to qualifying patent or exclusivity periods

Orange Book listings are not final determinations of validity or infringement. A generic applicant can challenge listed patents through Paragraph IV certifications, and a court can later hold a listed patent invalid, unenforceable, or not infringed.

What formulation patents protected cariprazine?

The Vraylar estate was not limited to the cariprazine molecule. Formulation and pharmaceutical-composition patents can protect commercial products after the broad compound patent becomes vulnerable.

Potential formulation claim categories include:

• Cariprazine hydrochloride in a defined capsule composition.
• Specific dosage strengths.
• Excipients and carrier systems.
• Stability characteristics.
• Solid-state or salt forms.
• Manufacturing parameters affecting purity or shelf life.
• Release, dissolution, or bioavailability properties.

These rights create a product-specific barrier. A generic applicant may avoid infringement by changing excipients, capsule composition, manufacturing conditions, or other non-active ingredients, but any change must remain pharmaceutically acceptable and bioequivalent under FDA standards.

The public settlement prevented a definitive ruling on whether Sun’s proposed formulation would infringe the asserted composition or formulation claims.

Did the case involve method-of-use patents?

Vraylar was approved for schizophrenia and bipolar I disorder indications. Method-of-use patents can protect treatment methods even when a generic applicant does not seek every branded indication.

The principal legal issue in such cases is whether the proposed generic labeling would encourage or require use covered by an asserted patent. A generic applicant may attempt a “section viii” carve-out for a patented indication, but the strategy is unavailable if the patent claims uses that cannot be removed without making the label misleading or incomplete.

The Allergan-Sun settlement avoided a judicial determination on induced infringement, skinny-label issues, or the scope of any Vraylar method-of-use claims.

How strong was the Vraylar patent estate?

The estate was commercially meaningful because it combined a core compound patent with later rights that could extend protection beyond the first expiration date. Its strength had four dimensions.

Broad chemical protection

The core cariprazine patent covered the active ingredient and provided the most direct barrier to generic substitution. A successful invalidity challenge to that patent could have materially accelerated generic entry.

Layered later patents

Later patents covering formulations, dosing, and therapeutic uses increased the number of issues a generic applicant had to defeat or design around. Layered protection often supports settlement even when the earliest compound patent is approaching expiration.

Regulatory leverage

The Paragraph IV filing triggered the 30-month stay, giving Allergan time to litigate before FDA approval. The stay did not guarantee long-term exclusivity, but it increased the value of a negotiated resolution.

Limited precedential validation

The estate did not receive a public trial judgment in this action. Its practical strength was therefore reflected in the settlement outcome and subsequent regulatory timing, not in a published validity or infringement decision.

Which companies challenged Vraylar exclusivity?

Vraylar faced ANDA activity from multiple generic manufacturers. Publicly reported Vraylar patent disputes included litigation involving Sun and other generic applicants, including companies such as Sandoz, Zydus, and Alembic in related proceedings or reported ANDA challenges.

The competitive pattern was typical for a high-value small-molecule product:

Challenger type	Strategy
First-wave ANDA filer	Paragraph IV challenge seeking early entry
Later ANDA filers	Follow-on challenges or reliance on settlement outcomes
Brand company	Assert core, formulation, and method-of-use patents
Generic company	Attack validity, narrow claim scope, or design around claims

The precise commercial rights granted to each challenger were governed by separate settlement agreements and were not necessarily identical.

What generic entry risks did the Sun case create?

The principal generic-entry scenarios were:

1. Allergan wins at trial, preserving the listed patent barriers through expiration.
2. Sun wins on validity or infringement, allowing earlier FDA approval and launch.
3. The parties settle with a delayed entry date.
4. The parties settle with an authorized generic or other supply arrangement.
5. Sun launches at risk after a court ruling or expiration of the statutory stay.

The settlement selected the third category based on publicly available docket information. Because the settlement terms were confidential, the precise launch date and any authorized-generic economics cannot be derived from the dismissal alone.

What revenue exposure did Vraylar create?

Vraylar had substantial revenue exposure by the time of the litigation. The product generated approximately $1.1 billion in net sales in 2020, according to AbbVie’s subsequent reporting. Sales increased materially in later years as prescribing expanded across schizophrenia and bipolar disorder indications.[1]

Metric	Approximate amount
Vraylar 2020 net sales	About $1.1 billion
Primary risk from early generic entry	Rapid price erosion and formulary substitution
Main commercial protection	Patent estate plus settlement-controlled entry
Acquirer exposed after 2020	AbbVie

For a product with more than $1 billion in annual sales, even a delayed generic launch can have substantial net present value. The financial effect depends on launch date, number of generic entrants, market-share capture, rebate structure, and whether an authorized generic is used to moderate price erosion.

Did the case involve biosimilar risk?

No. Vraylar is a small-molecule drug, and the Sun action was an ANDA case under the Hatch-Waxman framework. It was not a biosimilar action under the Biologics Price Competition and Innovation Act.

The relevant competitive risks were:

• ANDA approval.
• Paragraph IV patent litigation.
• Section viii labeling carve-outs.
• Generic substitution.
• Authorized-generic competition.
• Patent-term and settlement timing.

Biosimilar concepts such as reference-product exclusivity, interchangeability, and the BPCIA patent dance did not apply.

What licensing or settlement deal was reached?

Allergan and Sun entered a confidential settlement that resulted in dismissal of the case. No public filing identified the full economic terms.

The public record does not establish whether the agreement included:

• A license with a fixed launch date.
• A royalty-bearing license.
• An authorized-generic supply arrangement.
• A covenant not to sue.
• A restriction on Sun’s future product development.
• Any admission concerning patent validity or infringement.

Confidential Hatch-Waxman settlements are subject to federal reporting requirements. The FTC and Department of Justice review settlement agreements for potential antitrust concerns, but agency review does not disclose every economic term to the public.[2]

What is the current litigation status?

The civil action is closed following settlement and dismissal. There is no public merits judgment in Allergan USA v. Sun that invalidated the asserted Vraylar patents or found Sun’s ANDA product infringing.

The case remains relevant for three reasons:

• It confirms that Sun pursued an ANDA-based Paragraph IV challenge to Vraylar protection.
• It shows that Allergan relied on layered patent rights rather than the compound patent alone.
• It forms part of the broader generic-entry record affecting Vraylar after AbbVie acquired Allergan.

Key Takeaways

• Allergan USA v. Sun Pharmaceutical, No. 1:20-cv-01479, was a Delaware Hatch-Waxman action involving generic cariprazine, the active ingredient in Vraylar.
• Sun challenged Vraylar patent protection through a Paragraph IV ANDA certification.
• U.S. Patent No. 8,017,615 was the principal early compound patent, with an Orange Book-listed expiration in March 2027.
• Later formulation and method-of-use patents created additional barriers to generic entry.
• The case ended in a confidential settlement and dismissal, without a public ruling on patent validity, infringement, or enforceability.
• The action involved generic, not biosimilar, competition.
• Vraylar’s multibillion-dollar later sales trajectory made the settlement commercially material to Allergan and AbbVie.
• The exact Sun launch date, royalty terms, and any authorized-generic provisions were not publicly disclosed in the case docket.

FAQs About Allergan v. Sun Pharmaceutical and Vraylar

Was Sun the first company to challenge Vraylar patents?

Sun was among the early generic applicants to challenge Vraylar patent protection. Related Vraylar litigation involved other generic manufacturers.

Did Allergan win the Vraylar patent case?

There was no public merits judgment. The action ended through confidential settlement and dismissal.

When did the core Vraylar patent expire?

U.S. Patent No. 8,017,615 had an Orange Book-listed expiration in March 2027, while later patents could provide separate protection beyond that date.

Can a generic company sell cariprazine before every Vraylar patent expires?

Potentially. A generic applicant may obtain approval through a successful Paragraph IV challenge, a noninfringement or invalidity ruling, a settlement license, or a design-around that avoids enforceable patent claims.

Is Vraylar subject to biosimilar competition?

No. Vraylar is a small-molecule product subject to ANDA and Hatch-Waxman competition rather than biosimilar regulation.

References

1. AbbVie Inc. (2021). 2020 annual report. https://www.abbvie.com/investor-relations/financial-reports-and-filings/annual-reports.html
2. Federal Trade Commission. (2024). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. https://www.ftc.gov/legal-library/browse/agreements-filed-under-medicare-prescription-drug-improvement-modernization-act-2003
3. U.S. District Court for the District of Delaware. (2020). Allergan USA, Inc. v. Sun Pharmaceutical Industries Ltd., No. 1:20-cv-01479.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
5. U.S. Food and Drug Administration. (2024). Vraylar prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/centers for company products.